These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 7564328)

  • 1. Hemolysis on intravenous administration of a new calcium antagonist.
    Kleinbloesem CH; Siepmann M; Kirch W
    J Cardiovasc Pharmacol; 1995 Jun; 25(6):855-8. PubMed ID: 7564328
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of a new calcium antagonist, mibefradil (Ro 40-5967), on silent ischemia in patients with stable chronic angina pectoris: a multicenter placebo-controlled study. The Mibefradil International Study Group.
    Braun S; van der Wall EE; Emanuelsson H; Kobrin I
    J Am Coll Cardiol; 1996 Feb; 27(2):317-22. PubMed ID: 8557900
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluating the safety of mibefradil, a selective T-type calcium antagonist, in patients with chronic congestive heart failure.
    van der Vring JA; Bernink PJ; van der Wall EE; van Velhuisen DJ; Braun S; Kobrin I
    Clin Ther; 1996; 18(6):1191-206. PubMed ID: 9001836
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dose-response characteristics of mibefradil, a novel calcium antagonist, in the treatment of essential hypertension.
    Oparil S; Kobrin I; Abernethy DR; Levine BS; Reif MC; Shepherd AM
    Am J Hypertens; 1997 Jul; 10(7 Pt 1):735-42. PubMed ID: 9234827
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of the new calcium antagonist mibefradil (Ro 40-5967) on exercise duration in patients with chronic stable angina pectoris: a multicenter, placebo-controlled study. Ro 40-5967 International Study Group.
    Bakx AL; van der Wall EE; Braun S; Emanuelsson H; Bruschke AV; Kobrin I
    Am Heart J; 1995 Oct; 130(4):748-57. PubMed ID: 7572582
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adding the new calcium antagonist mibefradil to patients receiving long-term beta-blocker therapy results in improved antianginal and antiischemic efficacy.
    Schneeweiss A; Kobrin I; Charlon V; Caspi A; Marmor A; Sclarovsky S; Reisin L; Schlesinger Z
    Am Heart J; 1998 Feb; 135(2 Pt 1):272-80. PubMed ID: 9489976
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of chronic angina pectoris with combination mibefradil and beta-blocker therapy.
    Alpert JS
    Clin Cardiol; 1998 Feb; 21(2):129. PubMed ID: 9491954
    [No Abstract]   [Full Text] [Related]  

  • 8. Mibefradil, a novel calcium antagonist, in elderly patients with hypertension: favorable hemodynamics and pharmacokinetics.
    Bursztyn M; Kadr H; Tilvis R; Martina B; Oigman W; Talberg J; Kobrin I
    Am Heart J; 1997 Aug; 134(2 Pt 1):238-47. PubMed ID: 9313603
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antihypertensive properties of the novel calcium antagonist mibefradil (Ro 40-5967): a new generation of calcium antagonists? Mibefradil International Study Group.
    Bernink PJ; Prager G; Schelling A; Kobrin I
    Hypertension; 1996 Mar; 27(3 Pt 1):426-32. PubMed ID: 8698449
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-anginal and anti-ischemic effects of mibefradil, a new T-type calcium channel antagonist.
    Kobrin I; Bieska G; Charlon V; Lindberg E; Pordy R
    Cardiology; 1998; 89 Suppl 1():23-32. PubMed ID: 9570426
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lack of negative inotropic effects of the new calcium antagonist Ro 40-5967 in patients with stable angina pectoris.
    Portegies MC; Schmitt R; Kraaij CJ; Braat SH; Gassner A; Hagemeijer F; Pozenel H; Prager G; Viersma JW; van der Wall EE
    J Cardiovasc Pharmacol; 1991 Nov; 18(5):746-51. PubMed ID: 1723772
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The acute effects of intravenously administered mibefradil, a new calcium antagonist, on the electrophysiologic characteristics of the human heart.
    Rosenquist M; Brembilla-Perrot B; Meinertz T; Neugebauer A; Crijns HJ; Smeets JL; van der Vring JA; Fromer M; Kobrin I
    Eur J Clin Pharmacol; 1997; 52(1):7-12. PubMed ID: 9143860
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination of calcium channel blockers and beta blockers for patients with exercise-induced angina pectoris: a double-blind parallel-group comparison of different classes of calcium channel blockers. The Netherlands Working Group on Cardiovascular Research (WCN).
    van der Vring JA; Daniëls MC; Holwerda NJ; Withagen PJ; Schelling A; Cleophas TJ; Hendriks MG
    Angiology; 1999 Jun; 50(6):447-54. PubMed ID: 10378820
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety of mibefradil, a new once-a-day, selective T-type calcium channel antagonist.
    Kobrin I; Charlon V; Lindberg E; Pordy R
    Am J Cardiol; 1997 Aug; 80(4B):40C-46C. PubMed ID: 9286853
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Single- and multiple-dose mibefradil pharmacokinetics in normal and hypertensive subjects.
    Welker HA
    J Pharm Pharmacol; 1998 Sep; 50(9):983-7. PubMed ID: 9811158
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hemodynamic and humoral effects of the novel calcium antagonist Ro 40-5967 in patients with hypertension.
    Schmitt R; Kleinbloesem CH; Belz GG; Schroeter V; Feifel U; Pozenel H; Kirch W; Halabi A; Woittiez AJ; Welker HA
    Clin Pharmacol Ther; 1992 Sep; 52(3):314-23. PubMed ID: 1526090
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The interaction of the calcium antagonist RO 40-5967 with digoxin.
    Siepmann M; Kleinbloesem C; Kirch W
    Br J Clin Pharmacol; 1995 May; 39(5):491-6. PubMed ID: 7669484
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mibefradil (posicor).
    Giles TD
    Compr Ther; 1997 Nov; 23(11):761-3. PubMed ID: 9360806
    [No Abstract]   [Full Text] [Related]  

  • 19. Mibefradil withdrawn from the market.
    Billups SJ; Carter BL
    Ann Pharmacother; 1998; 32(7-8):841. PubMed ID: 9681103
    [No Abstract]   [Full Text] [Related]  

  • 20. Additional antianginal and anti-ischemic efficacy of mibefradil in patients pretreated with a beta blocker for chronic stable angina pectoris.
    Alpert JS; Kobrin I; DeQuattro V; Friedman R; Shepherd A; Fenster PE; Thadani U
    Am J Cardiol; 1997 Apr; 79(8):1025-30. PubMed ID: 9114758
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.